Zacks: Analysts Anticipate Teva Pharmaceutical Industries Limited (NYSE:TEVA) to Post $0.57 EPS

Equities analysts predict that Teva Pharmaceutical Industries Limited (NYSE:TEVA – Get Rating) will report $0.57 earnings per share (EPS) for the current fiscal quarter, Zacks reports. Five analysts have issued estimates for Teva Pharmaceutical Industries’ earnings. The lowest EPS estimate is $0.53 and the highest is $0.60. Teva Pharmaceutical Industries posted earnings of $0.59 per share during the same quarter last year, which indicates a negative year-over-year growth rate of 3.4%. The firm is expected to report its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that Teva Pharmaceutical Industries will report full-year earnings of $2.49 per share for the current year, with EPS estimates ranging from $2.46 to $2.53. For the next year, analysts forecast that the company will post earnings of $2.58 per share, with EPS estimates ranging from $2.46 to $2.67. Zacks Investment Research’s earnings per share calculations are an average based on a survey of analysts that that provide coverage for Teva Pharmaceutical Industries.

Teva Pharmaceutical Industries (NYSE:TEVA – Get Rating) last posted its quarterly earnings data on Tuesday, May 3rd. The company reported $0.55 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.55. The business had revenue of $3.66 billion during the quarter, compared to analysts’ expectations of $3.75 billion. Teva Pharmaceutical Industries had a negative net margin of 3.95% and a positive return on equity of 24.04%. The business’s revenue was down 8.1% on a year-over-year basis. During the same period last year, the firm posted $0.60 earnings per share.

A number of brokerages recently weighed in on TEVA. Zacks Investment Research upgraded shares of Teva Pharmaceutical Industries from a “sell” rating to a “hold” rating and set a $11.00 target price for the company in a report on Tuesday, April 12th. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a report on Thursday. Barclays upgraded shares of Teva Pharmaceutical Industries from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $11.00 to $13.00 in a report on Tuesday, April 5th. Sanford C. Bernstein raised shares of Teva Pharmaceutical Industries from a “market perform” rating to an “outperform” rating and set a $11.00 price objective for the company in a research note on Friday, March 25th. Finally, Piper Sandler lowered shares of Teva Pharmaceutical Industries from a “neutral” rating to an “underweight” rating and decreased their price objective for the stock from $11.00 to $7.00 in a research note on Wednesday, May 4th. One analyst has rated the stock with a sell rating, four have given a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $11.17.

In other Teva Pharmaceutical Industries news, VP David Matthew Stark sold 6,452 shares of the stock in a transaction that occurred on Monday, February 28th. The shares were sold at an average price of $8.14, for a total value of $52,519.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Eli Shani sold 5,311 shares of the firm’s stock in a transaction on Monday, February 28th. The shares were sold at an average price of $8.14, for a total transaction of $43,231.54. The disclosure for this sale can be found here. 0.74% of the stock is owned by corporate insiders.

Several institutional investors have recently added to or reduced their stakes in TEVA. Truist Financial Corp raised its holdings in shares of Teva Pharmaceutical Industries by 21.0% during the 3rd quarter. Truist Financial Corp now owns 135,857 shares of the company’s stock valued at $1,323,000 after purchasing an additional 23,566 shares in the last quarter. Mackenzie Financial Corp raised its holdings in shares of Teva Pharmaceutical Industries by 150.0% during the 3rd quarter. Mackenzie Financial Corp now owns 52,319 shares of the company’s stock valued at $510,000 after purchasing an additional 31,391 shares in the last quarter. Principal Financial Group Inc. raised its holdings in shares of Teva Pharmaceutical Industries by 1.5% during the 3rd quarter. Principal Financial Group Inc. now owns 153,879 shares of the company’s stock valued at $1,499,000 after purchasing an additional 2,233 shares in the last quarter. BlackRock Inc. raised its holdings in shares of Teva Pharmaceutical Industries by 2.0% during the 3rd quarter. BlackRock Inc. now owns 40,541,845 shares of the company’s stock valued at $394,877,000 after purchasing an additional 785,802 shares in the last quarter. Finally, CIBC Asset Management Inc raised its holdings in shares of Teva Pharmaceutical Industries by 4.8% during the 3rd quarter. CIBC Asset Management Inc now owns 110,369 shares of the company’s stock valued at $1,075,000 after purchasing an additional 5,052 shares in the last quarter. Institutional investors and hedge funds own 45.79% of the company’s stock.

Shares of NYSE:TEVA opened at $7.76 on Monday. The stock has a market capitalization of $8.56 billion, a price-to-earnings ratio of -14.11, a PEG ratio of 0.93 and a beta of 1.18. Teva Pharmaceutical Industries has a 1-year low of $7.23 and a 1-year high of $11.55. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.73 and a current ratio of 1.07. The company has a 50 day moving average price of $8.73 and a 200 day moving average price of $8.62.

About Teva Pharmaceutical Industries (Get Rating)

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams.

Read More